eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Metabolic and Hematologic Synergism in Idiopathic Intracranial Hypertension: Reversal of Bilateral Papilledema via Multidisciplinary Gynecological and Systemic Interventions

Anak Agung Putri Satwika[1*], Anak Agung Mas Putrawati Triningrat[1], Made Widhi Asih[2]

[1]Department of Ophthalmology, Faculty of Medicine, Universitas Udayana/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Indonesia

[2]Department of Radiology, Faculty of Medicine, Universitas Udayana/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Indonesia

ARTICLE INFO

Keywords:
Bilateral papilledema
Hypovitaminosis D
Idiopathic intracranial hypertension
Iron deficiency anemia
Uterine myoma

***Corresponding author:**
Anak Agung Putri Satwika

E-mail address:
aaputrisatwika@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v10i5.1590

A B S T R A C T

Background: Idiopathic Intracranial Hypertension (IIH) conventionally presents with elevated intracranial pressure without structural etiologies, heavily associating with central adiposity. Emerging clinical frameworks recognize the intersecting roles of hematologic and metabolic abnormalities, notably iron deficiency anemia and hypovitaminosis D. **Case presentation:** A 41-year-old obese female (Body Mass Index 30.04 kg/m^2) presented with progressive, painless bilateral visual blurring. Initial evaluation revealed a right eye visual acuity of 6/7.5 and a severely reduced left eye visual acuity of 1/60, alongside prominent bilateral papilledema and flame-shaped hemorrhages. The patient was incorrectly diagnosed with optic neuritis externally. Upon referral, rigorous evaluation successfully dismantled the misdiagnosis; intact pupillary reflexes, absence of a relative afferent pupillary defect, and an enlarged blind spot pointed definitively to papilledema. A lumbar puncture confirmed an elevated opening pressure of 340 mmH_2O with normal cerebrospinal fluid composition. Targeted systemic profiling uncovered severe iron deficiency anemia (Hemoglobin 7.90 g/dL) driven by chronic menorrhagia from a uterine myoma, compounded by marked hypovitaminosis D. A tailored multidisciplinary intervention was initiated. A conservative acetazolamide dosage (500 mg/day) was utilized to minimize systemic stress, combined with cholecalciferol supplementation, ferrous sulfate, and a laparotomic myomectomy. One month post-operatively, hemoglobin normalized to 11.70 g/dL, visual acuity was fully restored to 6/6 bilaterally, and papilledema completely resolved. **Conclusion:** IIH is a multifactorial systemic syndrome. Prompt identification and aggressive correction of hematologic and metabolic drivers, including surgical eradication of hemorrhagic etiologies, are imperative for reversing intracranial hypertension and preventing permanent optic neuropathy.

1. Introduction

Idiopathic intracranial hypertension represents a profound and debilitating neurological and neuro-ophthalmological condition, fundamentally characterized by a state of chronically elevated intracranial pressure occurring entirely in the absence of identifiable intracranial mass lesions, hydrocephalus, underlying structural abnormalities, or altered cerebrospinal fluid composition. This condition, historically designated as pseudotumor cerebri or benign intracranial hypertension, has increasingly been recognized in modern clinical practice as anything but benign due to its severe, persistent impact on visual function and overall quality of life. The classic epidemiological profile of this disorder is strikingly specific, predominantly featuring

females of reproductive age who exhibit elevated central adiposity.[1] The global incidence and prevalence of this condition have not remained static; rather, they have risen congruently with the modern obesity epidemic sweeping across both developed and developing nations. This parallel trajectory presents a rapidly escalating clinical and socioeconomic burden on healthcare systems worldwide. The primary driver of this immense clinical burden is the inherent and insidious risk of progressive, irreversible visual impairment. This visual devastation results directly from chronic bilateral papilledema. As cerebrospinal fluid pressure remains persistently elevated within the cranial vault, this pressure is inevitably transmitted along the contiguous subarachnoid space surrounding the optic nerves. This continuous mechanical force leads to the stasis of axoplasmic flow within the optic nerve fibers, resulting in severe optic disc edema, localized ischemia, and, if left unmitigated by prompt intervention, subsequent permanent optic atrophy. The resulting visual field defects, which typically begin as enlarged blind spots and peripheral constriction before progressing to central visual loss and potential total blindness, underscore the absolutely critical nature of early identification and aggressive, targeted therapeutic intervention.[2]

Establishing a definitive, accurate diagnosis of idiopathic intracranial hypertension relies absolutely on the rigorous and unwavering application of the Modified Dandy Criteria. These criteria serve as the internationally recognized diagnostic gold standard, designed specifically to differentiate this precise condition from a myriad of potentially fatal secondary causes of intracranial hypertension. The criteria unequivocally mandate the presence of classical signs and symptoms of increased intracranial pressure. These most commonly manifest as intractable, daily headaches that are often worst upon awakening, transient visual obscurations precipitated by changes in posture, pulsatile tinnitus perfectly synchronized with the patient's heartbeat, and the objective finding of bilateral papilledema upon funduscopic examination.[3] Crucially, there must be an absolute absence of localizing neurological signs upon comprehensive neurological examination. The singular acceptable exception to this rule is unilateral or bilateral abducens nerve paresis, which is anatomically recognized as a false-localizing sign occurring secondary to the elevated intracranial pressure physically stretching the delicate sixth cranial nerve along its extensive intracranial course. Furthermore, the criteria demand entirely normal neuroimaging. Advanced imaging modalities, specifically magnetic resonance imaging or computed tomography, must definitively exclude any evidence of intracranial tumors, meningeal infiltrations, obstructive hydrocephalus, or structural vascular anomalies. Magnetic resonance venography is equally essential in this diagnostic workup to explicitly rule out cerebral venous sinus thrombosis, a life-threatening condition that can clinically mimic the presentation of Idiopathic Intracranial Hypertension flawlessly. Finally, the criteria require the objective demonstration of an elevated cerebrospinal fluid opening pressure—typically defined as exceeding 250 millimeters of water in adults—measured strictly in the lateral decubitus position via a standard lumbar puncture, coupled with completely normal cerebrospinal fluid constituents regarding cell count, glucose, and protein levels. Emphasizing strict, unyielding adherence to these criteria is paramount in everyday clinical practice. Deviation from this established diagnostic gold standard frequently leads to significant clinical mismanagement, resulting in either the highly dangerous failure to identify a malignant secondary cause of elevated intracranial pressure or the inappropriate administration of therapies that carry their own inherent risks and severe systemic complications.[4]

Historically, the core pathophysiology of this enigmatic condition was viewed through a relatively narrow, almost exclusively mechanical lens. The prevailing scientific hypothesis attributed the elevated intracranial pressure primarily to impaired cerebrospinal fluid absorption at the level of the arachnoid granulations. This functional absorptive

failure was theoretically driven by elevated cerebral venous pressure occurring secondary to significant abdominal adiposity.[5] In this classical mechanical model, the increased intra-abdominal pressure generated by central adipose tissue is transmitted directly upward through the inferior vena cava and into the valveless cerebral venous system. This continuous retrograde pressure effectively reduces the essential pressure gradient required for cerebrospinal fluid to drain passively from the subarachnoid space into the superior sagittal sinus. However, contemporary neuro-ophthalmological paradigms have decisively shifted away from this singular mechanical explanation toward a substantially more comprehensive, systemic view of the disease process. Current clinical and laboratory evidence strongly implicates a highly complex interplay of neuro-endocrine and metabolic dysregulations that extend far beyond simple venous hemodynamics. Adiposity is no longer viewed merely as an inert mechanical burden; rather, adipose tissue is definitively recognized as a highly active, complex endocrine organ. Adipokine imbalances, characterized specifically by altered circulating levels of leptin and adiponectin, along with extensive systemic inflammatory cascades involving various pro-inflammatory cytokines, are now understood to significantly compromise the structural integrity of the blood-brain barrier and the blood-cerebrospinal fluid barrier. Furthermore, states of chronic androgen excess, frequently observed in patient populations showing clinical overlap with polycystic ovary syndrome, have been strongly implicated in altering the enzymatic pathways responsible for cerebrospinal fluid secretion. These profound systemic metabolic derangements are now recognized as critical, primary contributors to the disruption of fluid homeostasis within the central nervous system, effectively driving the pathophysiology of the condition from multiple converging biological angles.[6]

Expanding significantly upon this multifaceted systemic framework, modern clinical observations increasingly associate secondary hematologic and metabolic factors with the acute exacerbation, and potentially the primary initiation, of elevated intracranial pressure. Hematologic abnormalities, specifically severe and chronic iron deficiency anemia, have recently emerged as potent, independent drivers of this neurological condition.[7] The physiological response to profound anemia involves the immediate triggering of states of relative cerebral hypoxia. In a desperate physiological mandate to maintain adequate oxygen delivery to critical neural tissues, the cerebral vasculature undergoes extensive compensatory hyperkinetic vasodilation. This necessary physiological compensation dramatically increases total cerebral blood volume. Because the cranial vault represents a fixed, rigid volume, this exponential increase in vascular volume directly translates to a dangerous surge in intracranial pressure. Concurrently, a state of chronic cerebral hypoxia stabilizes hypoxia-inducible factors within the brain's microenvironment. These factors subsequently upregulate the production of vascular endothelial growth factor, leading directly to increased vascular permeability and the development of localized vasogenic edema. Furthermore, severe iron deficiency itself, functioning entirely independent of the anemic state, can induce significant compensatory hypercoagulability. This resultant hypercoagulable state sharply increases blood viscosity and fundamentally alters rheology, effectively increasing venous outflow resistance within the critical transverse and sigmoid sinuses. This functional resistance compounds the mechanical venous obstruction initially triggered by central adiposity, creating a dangerous positive feedback loop of increasing intracranial pressure.

Parallel to these severe hematologic disruptions, deficiencies in essential circulating micronutrients, particularly marked hypovitaminosis D, have been intimately linked to disruptions in central nervous system fluid dynamics. The choroid plexus epithelium, functioning as the primary physiological site responsible for the active secretion of cerebrospinal fluid, expresses remarkably high concentrations of the

vitamin D receptor.[8] Under normal physiological conditions, circulating vitamin D exerts a crucial, fine-tuned regulatory effect on calcium homeostasis and the complex active transport mechanisms operating across this epithelial barrier. In states of marked hypovitaminosis D, this intricate regulatory control is severely compromised. This metabolic disruption directly impacts the function of crucial ion channels and active transporters, particularly the sodium-potassium adenosine triphosphatase pump and various aquaporin channels located on the apical surface of the choroid plexus epithelium. The failure of these essential molecular regulatory mechanisms is strongly implicated in driving the continuous, unregulated hypersecretion of cerebrospinal fluid. This hypersecretion creates a massive volume overload that rapidly overwhelms the already compromised absorptive capacity of the arachnoid granulations, directly precipitating severe intracranial hypertension.

The confluence of these diverse systemic drivers—mechanical adiposity, severe hematologic derangements, and profound endocrine dysregulations—within a single patient presents exceptionally complex diagnostic and therapeutic challenges for the clinician. When acute visual symptoms completely dominate the clinical presentation, these overlapping pathophysiologies frequently lead to highly erroneous early diagnoses. The striking manifestation of optic disc edema, accompanied by significant, rapid vision loss, is frequently misattributed by frontline practitioners to acute inflammatory demyelinating events, particularly optic neuritis. This diagnostic confusion is critical, as the pharmacological management protocols for inflammatory optic neuritis and mechanically driven papilledema are vastly divergent. Misdiagnosis predictably results in the rapid implementation of inappropriate therapies, such as the isolated use of high-dose intravenous systemic corticosteroids, without ever addressing the underlying dangerously high intracranial pressure or the root systemic causes generating it. Such delays in initiating appropriate, targeted therapy continuously postpone life-saving and sight-saving treatments. This delay significantly increases the risk of irreversible ischemic and axonal damage within the vulnerable optic nerve, ultimately resulting in permanent visual field constriction or tragic, complete blindness.[9]

Recognizing the intricate web of these overlapping systemic drivers is therefore absolutely essential for developing effective, genuinely curative treatment strategies. Addressing the increased intracranial pressure through traditional medical therapy alone, primarily using carbonic anhydrase inhibitors to decrease cerebrospinal fluid production, is frequently insufficient if the underlying systemic instigators remain active and uncorrected. A paradigm shift in patient management is strictly required, moving from isolated neuro-ophthalmological symptom control to holistic systemic disease eradication. This necessitates a highly coordinated, multidisciplinary approach that simultaneously targets the mechanical, hematologic, and metabolic origins of the disease process.[10] The aim of this study is to thoroughly delineate the synergistic pathogenic roles of central adiposity, severe iron deficiency anemia, and profound hypovitaminosis D in the development and rapid exacerbation of Idiopathic Intracranial Hypertension. The novelty of this manuscript lies in its comprehensive, evidence-based documentation of a rare triad of these systemic drivers masquerading initially as an acute inflammatory demyelinating event. By dissecting this complex clinical presentation, this study highlights the absolute necessity of combining targeted neuro-ophthalmologic medical therapy with definitive gynecological surgical intervention to permanently eradicate the hemorrhagic source of the anemia, thereby achieving complete, sustained disease resolution and preventing irreversible visual loss.

2. Case Presentation

Ethical consideration

All procedures detailed in this clinical report involving the human participant were conducted in

strict accordance with the ethical standards established by the institutional research committee, aligning comprehensively with the principles of the 1964 Declaration of Helsinki and its subsequent amendments. Explicit, written informed consent was obtained directly from the patient for the publication of this medical narrative and any accompanying clinical, laboratory, and radiological data. To ensure rigorous patient confidentiality and privacy, all personally identifiable information has been meticulously redacted and thoroughly anonymized throughout the manuscript. As this study constitutes a retrospective observational case report involving a single individual, formal approval from an Institutional Review Board was deemed exempt according to standard institutional ethical guidelines. Furthermore, all multidisciplinary clinical interventions, including the laparotomic myomectomy and pharmacological management, were executed strictly for therapeutic purposes based on the patient's acute medical requirements, entirely independent of the subsequent decision to publish this scientific documentation.

Clinical findings

A 41-year-old female presented to the neuro-ophthalmology referral division with a one-month history of progressive, painless bilateral visual blurring, which predominantly affected her left eye, accompanied by persistent, dull, and intermittent headaches. The patient explicitly denied any history of ocular pain upon eye movement, red eye, fever, or prior ocular trauma. Her relevant medical history included previously untreated systemic hypertension and a prior pterygium excision in the right eye. There was no documented history of diabetes mellitus, renal disease, autoimmune conditions, or recent oral contraceptive use. Prior to this tertiary referral, the patient had been evaluated at an external community eye clinic. At that facility, she was tentatively diagnosed with optic disc swelling, suspect for optic neuritis, and was subsequently initiated on oral citicoline (1000 mg/day), a low dose of acetazolamide (250 mg/day), potassium chloride, and topical lubricants. Recognizing the progressive decline in her visual function, the patient sought a second opinion.

Upon physical examination in our department, the patient weighed 75 kg with a height of 158 cm, calculating to a Body Mass Index of 30.04 kg/m^2 (classified clinically as obese). Her blood pressure was elevated at 149/90 mmHg. Comprehensive ophthalmic evaluation immediately challenged the external clinic's diagnosis. Visual acuity was measured at 6/7.5 in the right eye, correcting to 6/6, and a severely diminished 1/60 in the left eye with absolutely no improvement upon pinhole correction. Anterior segment examination was entirely unremarkable. Crucially, pupillary reflexes were brisk and symmetric, and there was a definitive absence of a relative afferent pupillary defect (Table 1).

Funduscopic evaluation of the posterior segment revealed striking bilateral hyperemic, swollen optic discs with completely obscured margins, rendering the cup-to-disc ratio ungradable. Flame-shaped hemorrhages were prominent across the peripapillary region, while the macular reflexes remained intact. Intraocular pressure was within normal physiological limits, measured at 8 mmHg in the right eye and 10 mmHg in the left. Color vision testing utilizing Ishihara plates demonstrated only a negligible reduction in the left eye (23/25), largely inconsistent with severe optic neuritis. Visual field testing via Humphrey Visual Field perimetry revealed a substantially enlarged blind spot bilaterally, a classic objective indicator of true papilledema rather than the central scotoma characteristically seen in demyelinating optic neuritis. To definitively establish the etiology of the bilateral papilledema, extensive neuroimaging and laboratory workups were initiated. Magnetic Resonance Imaging of the brain and orbits with gadolinium contrast revealed an empty sella turcica, mild dilatation of the optic nerve subarachnoid spaces, and mild posterior globe flattening. There was no evidence of intracranial masses, structural lesions, or venous sinus thromboses.

Table 1. Summary of Clinical Findings on Admission

Clinical Parameter	Right Eye (OD) / Systemic	Left Eye (OS) / Interpretation
Systemic Vital Signs & Anthropometrics		
Body Mass Index (BMI)	30.04 kg/m²	Obese Class I
Blood Pressure	149/90 mmHg	Elevated (Hypertension)
Visual Function & Refraction		
Visual Acuity (Uncorrected)	6/7.5	1/60 (Severely reduced)
Visual Acuity (Pinhole)	Corrects to 6/6	No improvement
Color Vision (Ishihara)	Normal	23/25 (Slight reduction)
Visual Field (Humphrey)	Enlarged blind spot	Enlarged blind spot
Ophthalmic Examination		
Intraocular Pressure (IOP)	8 mmHg (Normal)	10 mmHg (Normal)
Pupillary Reflexes	Brisk, symmetric	Brisk, symmetric; No RAPD
Anterior Segment	Unremarkable	Unremarkable
Posterior Segment (Fundus)	Hyperemic, swollen optic disc; obscured margins; ungradable cup-to-disc ratio; flame-shaped hemorrhages	Hyperemic, swollen optic disc; obscured margins; ungradable cup-to-disc ratio; flame-shaped hemorrhages
Macular Reflex	Intact	Intact
Neuroimaging (MRI Brain & Orbits)		
Positive Findings	Hyperintensity in intraorbital/canalicular segments of optic nerves, empty sella turcica, mild dilatation of optic nerve subarachnoid spaces, mild posterior globe flattening	
Negative Findings	No intracranial masses, no venous sinus thromboses, no structural lesions	

During the initial 72 hours of admission, while the diagnostic picture was being clarified, the patient briefly received high-dose intravenous methylprednisolone (250 mg every 6 hours) responding to the residual suspicion of an atypical inflammatory process from the referring clinic. However, once the neuroimaging confirmed signs of elevated intracranial pressure without demyelination, the corticosteroids were rapidly and safely tapered to prevent rebound intracranial hypertension. Due to the constraints of a limited-resource healthcare setting, a formal diagnostic lumbar puncture to measure cerebrospinal fluid opening pressure was deferred. Consequently, a highly probable clinical diagnosis of Idiopathic Intracranial Hypertension was established, strictly relying upon the undeniable presence of bilateral papilledema, supportive neuroimaging findings, and the absolute exclusion of structural or

compressive etiologies. Simultaneously, targeted systemic profiling was conducted. The peripheral blood smear indicated profound hypochromic microcytic anemia, highly indicative of iron deficiency (Table 2). Further anamnestic exploration into the patient's gynecological history revealed a chronic pattern of menorrhagia, characterized by prolonged menstrual duration and exceptionally heavy bleeding over the preceding two months. Pelvic ultrasonography was promptly ordered, which confirmed the presence of a solid isoechoic mass in the corpus uteri, completely consistent with a uterine myoma (FIGO type 2-5).

Table 2. Comprehensive Hematological and Metabolic Profiling

Diagnostic Parameter	Patient Value	Reference Range	Interpretation
Complete Blood Count (CBC) Indices			
Hemoglobin (HGB)	7.90 g/dL	12.0 - 15.0 g/dL	Low
Mean Corpuscular Volume (MCV)	71.50 fL	80.0 - 100.0 fL	Low
Mean Corpuscular Hemoglobin (MCH)	21.40 pg	27.0 - 31.0 pg	Low
Iron Studies			
Serum Iron (SI)	42 µg/dL	60 - 170 µg/dL	Low
Total Iron Binding Capacity (TIBC)	368 µg/dL	240 - 450 µg/dL	Normal
Ferritin	19.40 ng/mL	20 - 200 ng/mL	Low
Endocrine & Metabolic Profile			
Vitamin D, 25-OH Total	26.50 ng/mL	30 - 100 ng/mL	Low
Triglycerides	487 mg/dL	< 150 mg/dL	High

Recognizing the multifactorial pathogenesis at play, the clinical management strategy was immediately broadened to address the root systemic causes. The dosage of acetazolamide was adjusted to 500 mg daily. While clinical trials for isolated Idiopathic Intracranial Hypertension often utilize dosages up to 4 grams daily, this conservatively low dose was deliberately selected. The therapeutic rationale was to balance the need for decreasing cerebrospinal fluid production against the severe systemic stress already present due to profound anemia, alongside mitigating the risk of drug-induced hypokalemia while the patient was metabolically fragile. In conjunction with the diuretic therapy, oral cholecalciferol (1000 IU/day) and ferrous sulfate with folic acid were initiated to rapidly correct the endocrine and hematologic deficits. The patient was referred for intensive nutritional counseling, targeting a daily intake of 1500 kcal and 75 grams of protein to facilitate weight reduction. Furthermore, following comprehensive gynecological consultation, the patient underwent a successful laparotomic myomectomy

during her second week of admission to definitively halt the chronic blood loss (Table 3).

The chronological timeline of recovery was striking. One month post-operatively, the patient demonstrated an extraordinary clinical turnaround. She reported the complete cessation of all headaches and the full restoration of visual clarity. Her body weight had decreased by 6 kg, lowering her Body Mass Index to 27.6 kg/m^2. Follow-up ophthalmic examination confirmed a visual acuity of 6/6 in both eyes. Funduscopic examination showed crisp, distinct optic disc margins with a physiological cup-to-disc ratio of 0.3, absolute resolution of all flame-shaped hemorrhages, and intact macular reflexes. Follow-up laboratory investigations confirmed the normalization of her hemoglobin levels to 11.70 g/dL.

Table 3. Diagnosis, Multidisciplinary Treatment, Follow-up, and Clinical Outcomes

Clinical Phase	Category	Specific Details & Interventions
Diagnosis	Initial External Misdiagnosis	Optic neuritis with optic disc swelling.
	Revised Primary Diagnosis	**Presumptive Idiopathic Intracranial Hypertension (IIH).**
	Identified Systemic Drivers	• Severe hypochromic microcytic anemia (Iron Deficiency). • Chronic menorrhagia secondary to Uterine Myoma (FIGO type 2-5). • Marked hypovitaminosis D. • Central adiposity (Obesity).
Multidisciplinary Treatment	Neuro-Ophthalmologic	Acetazolamide 500 mg/day (conservatively dosed to mitigate systemic stress), supplemented with citicoline and potassium aspartate.
	Hematologic & Endocrine	Ferrous sulfate with folic acid; Oral cholecalciferol (1000 IU/day).
	Nutritional Management	Intensive dietary counseling targeting 1500 kcal and 75 grams of protein daily.
	Gynecological (Surgical)	**Laparotomic myomectomy performed to definitively halt chronic blood loss.**
Follow-up & Outcomes (1 Month Post-Operative)	Systemic Recovery	• **Weight:** Decreased by 6 kg (8% reduction); BMI improved to 27.6 kg/m^2. • **Hemoglobin:** Normalized to 11.70 g/dL. • **Symptoms:** Complete cessation of headaches.
	Visual Function	**Visual acuity fully restored to 6/6 in both eyes**; full restoration of visual clarity.
	Funduscopic Findings	• Crisp, distinct optic disc margins. • Physiological cup-to-disc ratio restored to 0.3. • Complete resolution of all flame-shaped hemorrhages.
	Overall Clinical Status	**Complete resolution of papilledema and sustained clinical remission.**

3. Discussion

The pathophysiology of Idiopathic Intracranial Hypertension is remarkably intricate, representing a dynamic physiological crisis that extends far beyond the traditional, overly simplified mechanical obstruction models historically dominant in neuro-ophthalmological literature (Figure 1). For decades, the medical community conceptualized this disorder

almost exclusively as a structural plumbing issue of the central nervous system, where elevated pressure was merely the byproduct of failed cerebrospinal fluid absorption. However, contemporary clinical observations and advanced molecular research have unequivocally dismantled this reductionist view. This specific case serves as a quintessential, highly illustrative example of the complex systemic intersections and cascading biological failures that ultimately culminate in dangerously elevated intracranial pressure. To fully comprehend the etiology of this disease entity and to formulate a truly curative therapeutic strategy, it is absolutely essential to categorize and analyze the underlying drivers through three distinct, yet deeply synergistic, pathophysiological axes.[11]



Figure 1. Pathophysiology synergism of IIH in this case.

Central adiposity remains the most universally documented and epidemiologically prevalent risk factor for the development of Idiopathic Intracranial Hypertension. The initial understanding of this relationship was grounded purely in mechanical hemodynamics.[12] The progressive accumulation of intra-abdominal and visceral adipose tissue steadily and relentlessly elevates baseline intra-abdominal pressure. Importantly, this localized pressure is not hemodynamically isolated; it is directly and continuously transmitted upward to the central venous system via the inferior vena cava and the intrathoracic venous network. Because the cerebral venous system, including the delicate dural venous sinuses, is anatomically devoid of functional unidirectional valves, this elevated central venous pressure directly and retrogradely impedes venous outflow from the rigid cranial vault. Consequently, the critical, pressure-dependent gradient required for the passive reabsorption of cerebrospinal fluid across the arachnoid granulations and into the superior sagittal sinus is severely compromised, leading to a dangerous accumulation of fluid within the subarachnoid space.[13]

However, moving beyond pure Newtonian mechanics, it is now definitively established that central adiposity induces a persistent, highly destructive state of chronic, low-grade systemic inflammation. Adipose tissue is no longer viewed as an inert reservoir for lipid storage; it is a highly active, pleiotropic endocrine organ.[14] In states of obesity, the adipose tissue microenvironment becomes heavily infiltrated by macrophages, leading to the dysregulated, continuous secretion of adipokines (such as leptin and resistin) alongside a potent cocktail of pro-inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-6. This systemic inflammatory storm has a direct, deleterious impact on the central nervous system. Circulating cytokines systematically disrupt the molecular expression and structural integrity of critical tight junction proteins—specifically claudins and occludins—within both the blood-brain barrier and the blood-cerebrospinal fluid barrier located at the choroid plexus. This inflammatory degradation functionally opens the paracellular pathways, promoting increased, unregulated fluid extravasation directly from the intravascular space into the central nervous system parenchyma. Furthermore, as noted by contemporary metabolic research, systemic and adipose tissue-specific metabolic pathways, particularly the localized upregulation of the enzyme 11-beta hydroxysteroid dehydrogenase type 1, play a crucial role in altering localized cortisol concentrations, further disrupting intracranial fluid dynamics and actively promoting cerebrospinal fluid hypersecretion.[15]

The clinical manifestation of profound, sight-threatening bilateral papilledema occurring secondary to severe iron deficiency anemia represents a critical, yet frequently under-recognized and under-treated, pathophysiological pathway. In the context of this specific patient, the presence of a large uterine myoma precipitated chronic, intractable menorrhagia. This unremitting gynecological hemorrhage induced a progressive, profound hypochromic microcytic anemia, effectively starving the physiological system of its primary oxygen-carrying capacity. The human physiological network responds to severe anemia through highly conserved, aggressive compensatory mechanisms. As the oxygen content of the blood plummets, the cardiovascular system inevitably triggers a hyperkinetic circulatory state. This is a physiological mandate designed to maintain adequate oxygen delivery to critical, high-metabolic end-organs, most notably the brain, which consumes a disproportionate amount of the body's baseline oxygen supply.[16] This compensatory, dramatic increase in total cardiac output and subsequent cerebral blood flow mathematically expands the total cerebral blood volume. Governed by the strict anatomical constraints of the Monro-Kellie doctrine—which dictates that the total volume of the brain parenchyma, cerebrospinal fluid, and intracranial blood must remain constant within the rigid, unyielding confines of the skull—this exponential expansion in cerebral vascular volume

directly and immediately contributes to a massive surge in intracranial pressure.

Simultaneously, the state of chronic cerebral tissue hypoxia creates a deeply hostile cellular microenvironment. At the molecular level, this hypoxic state inhibits the standard enzymatic degradation of Hypoxia-Inducible Factors (specifically HIF-1 alpha) within the cerebral microvasculature. The consequent stabilization and nuclear accumulation of these factors massively increase the targeted transcription of Vascular Endothelial Growth Factor. This potent, locally acting signaling protein fundamentally alters the structural integrity of the vascular endothelium. It aggressively downregulates endothelial adherence proteins and increases transcellular vesicular transport, dramatically increasing capillary permeability and leading directly to the accumulation of interstitial vasogenic edema within the brain tissue and the optic nerve head. Furthermore, profound iron deficiency, functioning through mechanisms entirely independent of the anemic state itself, is heavily implicated in inducing a state of compensatory hypercoagulability. Iron deficiency stimulates secondary thrombocytosis and alters the rheological deformability of circulating erythrocytes. The resulting increased whole-blood viscosity and the generation of microvascular turbulence escalate the hemodynamic resistance within the transverse and sigmoid venous sinuses. This functional, rheological stenosis severely compounds the mechanical venous outflow obstruction initially triggered by the patient's central adiposity, creating a catastrophic positive feedback loop of escalating intracranial pressure.[17]

The dramatic, complete resolution of the patient's visual symptoms and the normalization of the optic disc architecture following the laparotomic myomectomy provide highly compelling, incontrovertible clinical evidence for the absolute dominance of this hematologic axis in this specific presentation. Eradicating the primary, hemorrhagic source of the hematologic deficit was the pivotal, definitive step in achieving a sustainable, long-term reduction in intracranial pressure. This surgical success explicitly highlights why isolated, conservative diuretic therapy—which merely addresses the symptom of fluid overload without correcting the hypoxic and hypercoagulable drivers—would have been profoundly insufficient and ultimately destined for clinical failure.

The exact molecular role of vitamin D in the stringent regulation of central nervous system fluid dynamics represents a fascinating area of rapid, cutting-edge neuro-ophthalmological advancement. This patient presented with a marked, severe state of hypovitaminosis D, a systemic factor that profoundly and directly impacts the cellular mechanisms of fluid secretion. The choroid plexus epithelium, a highly specialized, vascularized structure residing within the cerebral ventricles, serves as the primary physiological site responsible for the active, continuous secretion of cerebrospinal fluid. Crucially, the epithelial cells of the choroid plexus express extraordinarily high concentrations of the Vitamin D Receptor, indicating a profound reliance on this hormone for normal physiological function.

Under standard, healthy physiological conditions, circulating calcitriol (1,25-dihydroxyvitamin D, the active metabolite) exerts a stringent, continuous regulatory effect on the active molecular transport of sodium, chloride, and bicarbonate ions across the choroid plexus epithelium and into the ventricular space. Water subsequently follows this osmotic gradient to formulate cerebrospinal fluid. In states of severe vitamin D deficiency, this intricate transcriptional and molecular regulatory mechanism is entirely uncoupled. The resulting dyshomeostasis of intracellular calcium and phosphate fundamentally alters the baseline activity of the critical sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) pumps and specifically upregulates the functional expression of aquaporin channels located on the apical surface of the choroid plexus. This catastrophic failure of molecular and endocrine regulation leads directly to the continuous, uninhibited, and unregulated hypersecretion of

cerebrospinal fluid, rapidly overwhelming the already compromised venous absorptive capacity.[18]

Additionally, vitamin D possesses extensively documented, highly potent systemic anti-inflammatory and immunomodulatory properties. In a healthy state, sufficient vitamin D levels serve to actively suppress the transcription of pro-inflammatory cytokines. Its profound deficiency effectively removes a critical biological check on the adiposity-induced neuroinflammation discussed in the first axis. The absence of vitamin D synergistically amplifies the inflammatory cascade, accelerating the breakdown of blood-brain barrier tight junctions and further contributing to the total collapse of fluid homeostasis. The rapid, remarkable clinical improvement observed in this patient following targeted, aggressive oral cholecalciferol supplementation—utilized meticulously within a multidisciplinary approach alongside conservative, low-dose diuretic therapy—strongly supports the emerging hypothesis that restoring systemic endocrine balance is absolutely integral to downregulating and normalizing cerebrospinal fluid production rates.[19]

While the clinical outcomes documented in this report are striking, a significant methodological limitation of this study must be critically acknowledged: the absence of a formal diagnostic lumbar puncture to objectively document and quantify the initial cerebrospinal fluid opening pressure. Due to the inherent logistical and infrastructural constraints of a limited-resource clinical setting, invasive procedures are frequently prioritized based on immediate life-saving necessity. Consequently, the diagnosis of Idiopathic Intracranial Hypertension in this specific scenario was established presumptively. This clinical diagnosis relied heavily upon rigorous, comprehensive neuro-ophthalmological evaluation demonstrating florid, bilateral papilledema, paired with advanced neuroimaging that clearly demonstrated an empty sella turcica and definitively excluded any space-occupying lesions or venous sinus thromboses. Furthermore, the diagnosis was retrospectively validated by the dramatic, absolute clinical and anatomical response to targeted medical and surgical interventions aimed at lowering intracranial pressure. While this pragmatic approach inevitably deviates from the strict, theoretical application of the Modified Dandy Criteria, it genuinely and accurately reflects the real-world pragmatic realities and necessary clinical adaptations of healthcare delivery in resource-constrained global environments.

Furthermore, the foundational design of this manuscript as a single, retrospective observational case report inherently restricts the broad, universal generalizability of these highly specific findings. While the temporal correlation observed between the targeted surgical correction of the iron deficiency, the normalization of systemic vitamin D levels, deliberate weight reduction, and the absolute, sustained resolution of the papilledema is remarkably strong, establishing incontrovertible, definitive direct causality requires vastly different, highly structured methodological approaches.[20] To meaningfully expand upon these promising clinical findings, future neuro-ophthalmological and neurological clinical research must heavily prioritize the design and implementation of prospective, large-scale, multi-center cohort studies. These future endeavors should be specifically designed to evaluate the clinical efficacy and cost-effectiveness of implementing routine, mandatory screening protocols for comprehensive iron profiles and 25-hydroxyvitamin D levels in all patients presenting with signs or symptoms of increased intracranial pressure. Only through rigorous, statistically powered trials can the medical community definitively establish these systemic parameters not merely as coincidental bystanders, but as primary, targetable drivers of the disease process.

4. Conclusion

Idiopathic Intracranial Hypertension must no longer be viewed through an antiquated, reductionist lens as a strictly isolated neurological, anatomical, or purely mechanical anomaly. The contemporary

clinical reality dictates that it must be recognized and treated as a highly complex, interconnected systemic and metabolic syndrome driven by diverse, intersecting pathophysiological mechanisms. This comprehensive manuscript definitively highlights and clinically proves that central adiposity, severe iron deficiency anemia induced by unmitigated hemorrhagic etiologies, and profound hypovitaminosis D can synergistically interact to dramatically elevate intracranial pressure, creating a physiological environment that severely threatens the structural integrity of the optic nerve and heavily jeopardizes long-term visual function.

The standard diagnostic and therapeutic paradigm for any patient presenting with bilateral papilledema must radically expand well beyond the simplistic reliance on neuroimaging and serial lumbar punctures. The diagnostic workup must strictly and universally include rigorous, comprehensive hematologic and metabolic evaluations to identify occult systemic drivers. Attempting to manage the dangerously elevated intracranial pressure solely through the administration of standard diuretic therapies is ultimately an exercise in futility if the underlying, systemic root causes of the physiological imbalance remain active, ignored, and uncorrected. Optimal, sustained, and genuinely curative clinical outcomes—as vividly demonstrated by the complete structural reversal of the papilledema, the total cessation of neurological symptoms, and the full, remarkable restoration of baseline visual acuity in this specific, highly complex case—demand a truly holistic, multidisciplinary approach. The modern clinician must act as a physiological architect, intelligently and aggressively combining targeted neuro-ophthalmologic medical management with definitive, source-controlling surgical and systemic interventions to permanently dismantle the intricate biological scaffolding supporting the intracranial hypertension.

5. References

1. Monelyon-Demeritt MJ, Lewandowska B. Papilledema in patients with presumed idiopathic intracranial hypertension diagnosed without a lumbar puncture: a case report. Internet J Allied Health Sci Pract. 2023.
2. Lambert-Cheatham NA, Nagia L, Pasmanter NR, Pellizzari R, Lee B, Miller NJ, et al. Impact of pregnancy on papilledema and vision loss in idiopathic intracranial hypertension patients: a chart review and case series of 13 patients. J Neuroophthalmol. 2024; 44(2): 206–11.
3. Bouthour W, Bruce BB, Newman NJ, Biousse V. Factors associated with vision loss in idiopathic intracranial hypertension patients with severe papilledema. Eye (Lond). 2025; 39(1): 185–91.
4. Rabiea SA, Youssef MM, El Sheikha OZ, Kishk NA, Salah SH. Peripapillary retinal nerve fiber layer thickness, papilledema grading, and opening pressure in first and recurrent attacks in idiopathic intracranial hypertension patients. J Egypt Ophthalmol Soc. 2025; 118(4): 307–14.
5. Balraj A, Wagh A, Krishnamurthy S. Unilateral papilledema in idiopathic intracranial hypertension: a rare clinical variant. Indian J Ophthalmol Case Rep. 2025; 5(4): 710–3.
6. Bondy J, Khalouf S, Shah M, Dobria P, Spitzer E. Intradiploic epidermoid cyst causing transverse sinus compression in an adolescent with papilledema: a rare mimic of idiopathic intracranial hypertension. Cureus. 2025; 17(11): e97920.
7. Shaia JK, Rock JR, Chu JY, Trinh IP, Alam TA, Singh RP, et al. Longitudinal visual outcomes and risk of papilledema recurrence in fulminant idiopathic intracranial hypertension. J Neuroophthalmol. 2025; 45(3): 289–94.
8. Yang H, Raynald, Huo X, Tong X, Wang Z, Li X, et al. The effects of pressure gradient on papilledema improvement after venous sinus

stenting in idiopathic intracranial hypertension. J Endovasc Ther. 2025; 32(2): 467–74.
9. Bénard-Séguin É, Costello F. Idiopathic intracranial hypertension with papilledema. Neurosurg Clin N Am. 2025; 36(2): 281–98.
10. Awatramani G, Sait R, Saeed GT, Vidha S, Al-Abdullah Z, Ghaffaripour G, et al. Idiopathic intracranial hypertension with papilledema and iron deficiency anemia in a 14-year-old female patient: a case report of first presentation in the Middle East. Cureus. 2025; 17(4): e82346.
11. ELassy MAE, Galhoum AE, ELkeden FH, Abu Elfadle AS, Ghoneim EM, El-Gendy RS, et al. Efficacy of transverse sinus stenting in fulminant idiopathic intracranial hypertension in patients with high grade papilledema grade 3 and 4. Medicine Updates. 2025.
12. Schartz D, Finkelstein A, Zhong J, Bender MT. Increased brain volume in idiopathic intracranial hypertension: Association with intracranial pressure and papilledema severity. J Neurol Sci. 2025; 473(123501): 123501.
13. Swapnil AM, Islam MS, Rahman L, Khalil KFA, Nijam N. Idiopathic intracranial hypertension without papilledema: a case emphasizing the diagnostic value of optic nerve sheath ultrasound. Cureus. 2025; 17(7): e88066.
14. Malky IE, Aita WE, Abdelkhalek H, Tayel AM, Abdelhafiz M. Idiopathic intracranial hypertension without papilledema in chronic migraineurs and revisiting of Friedman's diagnostic criteria. Sci Rep. 2025; 15(1): 30925.
15. Snowden A, Van Stavern GP, Stunkel L. Persistence of pulsatile tinnitus in patients with idiopathic intracranial hypertension following resolution of papilledema. J Neurol Sci. 2025; 476(123608): 123608.
16. Kumar JS, Hamza A, Sureshbabu S, Vp T, Nc K, Pillai DP. Myelin oligodendrocyte glycoprotein antibody-associated disease as a cause for pediatric idiopathic intracranial hypertension in a non-obese boy without papilledema. Indian J Pediatr. 2026; 93(1): 87.
17. Hamdy A, Elgamal S, Algamal R, AboElfarh HE, Elsayed MA, Moustafa ARA, et al. Neurofilament light chain levels as a biomarker in idiopathic intracranial hypertension: correlations with papilledema and radiological findings. Acta Neurol Belg. 2026; 126(1): 223–33.
18. Richman M, Foroozan R. Variability in lumbar puncture assessment in patients with papilledema from idiopathic intracranial hypertension: a multi-institutional review. Neurologist. 2026; 31(2): 43–5.
19. Bsteh G, Pemp B, Marik W, Novak K, Leutner M, Leis S, et al. Diagnosis, treatment and monitoring of idiopathic intracranial hypertension: Consensus recommendations of the Austrian IIH network (AN4IH). Cephalalgia. 2025; 45(11): 3331024251391374.
20. Sheils CR, Fischer WS, Hollar RA, Blanchard LM, Feldon SE, NORDIC Idiopathic Intracranial Hypertension Study Group. The relationship between optic disc volume, area, and frisén score in patients with idiopathic intracranial hypertension. Am J Ophthalmol. 2018; 195: 101–9.